CABG patients 'at greater risk of bleeds with DAPT'
Stratification of patients based on revascularisation procedures may assist in balancing the risks of recurrent ischaemic and bleeding events, researchers say
The risk of bleeding with antithrombotic therapy may outweigh the threat of recurrent ischaemic events in many survivors of acute coronary syndrome who undergo CABG, an Australian study suggests.
The modelling shows, however, that most post-acute coronary syndrome (ACS) patients will benefit from extended antithrombotic therapy, with the 6-18 months risk of ischaemic events exceeding that of major bleeds.
The researchers, led by interventional cardiologist Professor David Brieger at Sydney’s Concord Hospital,
